bluebird bio has scored a series of firsts with its life-changing beta-thalassemia gene therapy, Zynteglo, after the European Medicines Agency today recommended that the product should be marketed in the EU.
Zynteglo, formerly referred to as LentiGlobin, is the first gene therapy recommended for approval in the EU for transfusion-dependent β-thalassemia...








